Core Viewpoint - Watson Bio has received approval for a clinical trial of a freeze-dried mRNA vaccine for herpes zoster, developed in collaboration with several partners [2] Company Summary - Watson Bio's subsidiary, Beijing Watson Innovation Biotechnology Co., Ltd., along with Yunnan Vaccine Laboratory Co., Ltd. and Yuxi Watson Biotechnology Co., Ltd., is involved in the development of the mRNA vaccine [2] - The vaccine development is a joint effort with Fudan University and Shanghai Blue Magpie Biomedical Co., Ltd. [2] Industry Summary - The approval from the National Medical Products Administration marks a significant step in the advancement of mRNA vaccine technology in the field of infectious diseases [2]

Core Viewpoint - Watson Bio (300142.SZ) announced that its subsidiary, Beijing Watson Innovation Biotechnology Co., Ltd., along with Yunnan Vaccine Laboratory Co., Ltd. and Yuxi Watson Biotechnology Co., Ltd., has jointly developed and applied for clinical trials of a lyophilized varicella-zoster virus mRNA vaccine in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd. The vaccine has recently received the Clinical Trial Approval Notification from the National Medical Products Administration, allowing the commencement of clinical trials aimed at preventing shingles [1]. Group 1 - Watson Bio's subsidiary has received approval for clinical trials of a new mRNA vaccine targeting shingles [1] - The vaccine development involves collaboration with notable institutions including Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd. [1] - The approval indicates that the vaccine meets the necessary requirements for drug registration as of September 18, 2025 [1]

Core Viewpoint - Watson Bio (300142) has recently received approval from the National Medical Products Administration for a clinical trial of a freeze-dried varicella-zoster virus mRNA vaccine, developed in collaboration with several partners [1] Group 1 - The clinical trial approval was granted for a vaccine developed by Watson Bio's subsidiary, Beijing Watson Innovation Biotechnology Co., Ltd., in partnership with Yunnan Vaccine Laboratory Co., Ltd., Yuxi Watson Biotechnology Co., Ltd., Fudan University, and Shanghai Blue Magpie Biomedical Co., Ltd. [1]

Core Viewpoint - Watson Bio's subsidiary has received approval for clinical trials of a freeze-dried mRNA vaccine for herpes zoster from the National Medical Products Administration of China [1] Group 1: Company Developments - Watson Bio, along with Fudan University and Shanghai Bluebird Biomedicine, has jointly developed and applied for clinical trials of the mRNA vaccine [1] - The vaccine aims to stimulate the immune system to produce immunity against the herpes zoster virus for prevention purposes [1] Group 2: Regulatory Approval - The clinical trial approval notice was issued under the registration categories of preventive biological products [1] - The approval was based on compliance with the relevant requirements of the Drug Administration Law and Vaccine Administration Law of the People's Republic of China [1]

Core Viewpoint - Watson Bio has received approval from the National Medical Products Administration for clinical trials of a freeze-dried varicella-zoster virus mRNA vaccine, developed in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd [1] Group 1: Company Developments - Watson Bio's subsidiary, Beijing Watson Innovation Biotechnology Co., Ltd., along with Yunnan Vaccine Laboratory Co., Ltd. and Yuxi Watson Biotechnology Co., Ltd., is involved in the joint development of the mRNA vaccine [1] - The clinical trial approval notification number is 2025LP03354; 2025LP03355, and the vaccine is classified as a preventive biological product [1] - The approval indicates that the vaccine meets the requirements for drug registration as per Chinese regulations, allowing for clinical trials aimed at preventing shingles [1] Group 2: Financial Performance - For the first half of 2025, Watson Bio's revenue composition is as follows: self-developed vaccines account for 94.82%, intermediate product revenue 4.67%, other business 0.26%, and service revenue 0.24% [1] - As of the report date, Watson Bio's market capitalization stands at 18.1 billion yuan [1]

Core Viewpoint - Watson Bio (300142.SZ) announced that its subsidiaries have received approval from the National Medical Products Administration for a clinical trial of a freeze-dried mRNA vaccine for herpes zoster, developed in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd [1] Group 1 - The clinical trial approval was granted for the freeze-dried herpes zoster virus mRNA vaccine, which is intended for the prevention of herpes zoster [1] - The vaccine application was reviewed and found to meet the requirements for drug registration, with the trial set to commence [1] - The approval notification was issued on September 18, 2025, indicating a timeline for the clinical trial process [1]

证券代码：300142 证券简称：沃森生物 公告编号：2025-077 标准后，方能向国家药品监督管理局申请药品上市许可。临床研究期间，疫苗的 临床试验进度和研究结果等均具有一定的不确定性。敬请广大投资者谨慎决策， 注意投资风险。 特此公告。 云南沃森生物技术股份有限公司 云南沃森生物技术股份有限公司 关于子公司收到冻干带状疱疹病毒 mRNA 疫苗《药物临床试 验批准通知书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 由云南沃森生物技术股份有限公司（以下简称"公司"或"沃森生物"）子 公司北京沃森创新生物技术有限公司、云南疫苗实验室有限公司、玉溪沃森生物 技术有限公司与复旦大学、上海蓝鹊生物医药有限公司（以下简称"蓝鹊生物"） 联合研发并共同申请临床试验的冻干带状疱疹病毒 mRNA 疫苗，于近日获得国家 药品监督管理局签发的《药物临床试验批准通知书》。通知书编号为： 2025LP03354；2025LP03355。注册分类：预防用生物制品。审批结论：根据《中 华人民共和国药品管理法》《中华人民共和国疫苗管理法》及有关规定，经审查， 2025年9月1 ...

证券代码：300142 证券简称：沃森生物 公告编号：2025-078 云南沃森生物技术股份有限公司 关于召开2025年第一次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 经云南沃森生物技术股份有限公司（以下简称"公司"）第五届董事会第 三十三次会议审议通过，决定于 2025 年 12 月 19 日（星期五）召开公司 2025 年第一次临时股东大会。本次股东大会的会议通知已于 2025 年 11 月 29 日公布 于中国证监会指定的创业板信息披露网站巨潮资讯网。本次股东大会将采用现 场会议与网络投票相结合的方式召开。现就本次股东大会的相关事宜再次提示 公告如下： 一、召开会议的基本情况 1、股东大会届次：2025 年第一次临时股东大会 2、股东大会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创 业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司 章程》的有关规定。 4、会议时间： （1）现场会议时间：20 ...

Core Viewpoint - Watson Bio announced that its subsidiaries, in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd., have received approval from the National Medical Products Administration for clinical trials of a lyophilized varicella-zoster virus mRNA vaccine [1] Group 1 - The clinical trial approval notification was issued under the registration categories of preventive biological products [1] - The approval was based on compliance with the Drug Administration Law and Vaccine Administration Law of the People's Republic of China [1] - The application for the clinical trial was accepted on September 18, 2025, and the vaccine meets the requirements for drug registration [1]

Core Viewpoint - The board's unanimous vote of "9 in favor, 0 against" is undermined by a notable abstention from director Fan Yongwu, highlighting concerns over a nearly 2 billion yuan cash expenditure amid performance pressures and governance issues at Watson Bio [1][6]. Group 1: Financial Challenges - Watson Bio plans to spend approximately 19.98 billion yuan to acquire a 13.78% stake in its subsidiary Yuxi Watson, despite only reporting a net profit of 1.63 billion yuan for the first three quarters, indicating a cash outflow equivalent to 12 times its quarterly profit [2][8]. - The acquisition involves payments of 16.39 billion yuan to "Huixiang Yuetai" and 3.59 billion yuan to "Tianjin Lanwo," with no expected enhancement in product lines or market expansion, raising concerns about prioritizing cash usage [2][8]. Group 2: Valuation Paradox - The valuation logic of the transaction appears contradictory during a downturn in the vaccine market, with Yuxi Watson's estimated value at around 14.5 billion yuan, while Watson Bio's total market capitalization is only about 19.5 billion yuan [9][10]. - This discrepancy raises questions about whether the subsidiary is overvalued or if the parent company's stock is undervalued, suggesting that a more rational approach would be to repurchase shares rather than overpay for non-tradable subsidiary equity [10]. Group 3: Governance Concerns - The transaction involves complex relationships, with one counterparty, "Huixiang Yuetai," having partners that include members of Watson Bio, suggesting a potential internal transaction [4][10]. - The decision to use scarce cash for a high-valuation acquisition amid uncertain future profitability raises doubts about whether this move is aimed at long-term growth or facilitating exits for specific investors [4][10]. - Watson Bio's history of controversial capital operations, including past attempts to sell subsidiaries at low prices, reflects a governance structure lacking effective control, leading to potential internal management issues [5][11].